The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Therapeutically targeting pDCs in multiple myeloma
Dharminder Chauhan, JD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, explains how targeting bone marrow accessory cells in the tumor microenvironment, such as plasmacytoid dendritic cells (pDCs) which are in excess within multiple myeloma, could be used to increase responsiveness of the tumor cells to conventional and novel immune therapies. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.
